ESMO 2026 | CATALINA-1: ixotatug vedotin, a claudin 6-targeted ADC, in germ cell tumors
Darren Feldman, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses safety and efficacy results from the Phase I CATALINA-1 study (NCT05103683) of ixotatug vedotin, a claudin 6-targeted antibody-drug conjugate (ADC), as monotherapy in heavily pretreated patients with germ cell tumors, including those with disease progression after high-dose chemotherapy with autologous stem cell transplantation. Meaningful clinical activity was observed, including in transplant-refractory disease, with a safety profile consistent with prior experience. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
